Cyclomedica is a pioneering global leader in nuclear medicine and molecular imaging, specializing in groundbreaking functional lung imaging technologies. Their flagship product, Technegas®, has revolutionized pulmonary diagnostic capabilities since its first clinical approval in 1986. The company has established itself as a critical innovator in respiratory medicine, delivering advanced imaging solutions that help clinicians diagnose, assess, and monitor various lung-related conditions.
The company’s core technology, Technegas®, has made significant strides in expanding beyond traditional pulmonary embolism (PE) detection. Currently distributed in 65 countries and having completed over 4.7 million patient procedures, Technegas® is now being utilized for a wide range of respiratory challenges, including chronic thromboembolic pulmonary hypertension (CTEPH), chronic obstructive pulmonary disease (COPD), asthma, and even identifying COVID-19 complications. By combining advanced imaging techniques with artificial intelligence, Cyclomedica is continuously pushing the boundaries of pulmonary care.
Based in Australia with a growing international presence, Cyclomedica is committed to improving clinical outcomes for patients suffering from lung-related conditions. Their approach goes beyond traditional medical technology by actively pursuing research initiatives to expand the applications of Technegas®. With a clear vision encapsulated in their motto “Aspire. Inspire. Illuminate,” the company continues to drive innovation in nuclear medicine, transforming how healthcare professionals diagnose, plan treatments, and ultimately improve patient care in the complex field of respiratory medicine.
Join +20,000 subscribers receiving alerts.
Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.
StockWire X delivers fast, reliable, and actionable insights into significant developments across global markets, with coverage spanning technology, biotechnology, healthcare, financials, and emerging industries. Our mission is to provide clear, data-driven content that empowers investors to identify opportunities and make informed decisions ahead of the market.
Our network spans key financial and investment hubs worldwide, ensuring subscribers receive timely updates on market-moving announcements, news, macroeconomic trends, and corporate developments.
Use of Technology
We harness advanced technologies to enhance the speed, accuracy, and relevance of our reporting.
While technology accelerates our workflow, every piece of content is selected, validated, and published by human professionals, in accordance with best practices for accuracy, transparency, and investor value. This hybrid approach ensures speed without compromising editorial integrity.
Feedback and Accuracy
We are committed to accuracy and fairness in our reporting. If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.
StockWire X provides readers with access to market news, educational content, and commentary from financial services professionals, industry experts, and companies (“Contributors”).
StockWire X does not hold an Australian Financial Services Licence (AFSL) and relies on the exemption available under section 911A(2)(eb) of the Corporations Act 2001 (Cth) in respect of any financial product advice provided.
Any advice or information published by StockWire X is general in nature only and has been prepared without taking into account your personal objectives, financial situation, or needs. Before acting on any information, you should consider whether it is appropriate for your circumstances and seek independent, licensed financial advice. You should also obtain and read any relevant Product Disclosure Statement (PDS) or other offer document before making an investment decision.
StockWire X makes no guarantee as to the accuracy, completeness, or timeliness of the information provided, and accepts no responsibility for any loss arising from reliance on it. All content is published in good faith for informational purposes only.
StockWire X may have commercial relationships with some contributors or companies mentioned in our content. Any such relationships will be disclosed where relevant.
If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.
